Report Overview

Indian Ankylosing Spondylitis Drugs Market size stood at USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period.

Ankylosing spondylitis is one of the chronic inflammatory disease which affects the spine. It is a one type of arthritis, in which spine bones grow or may bind together, which causes the spine to become rigid. Symptoms of ankylosing spondylitis are pain and stiffness from the neck to the lower back, bony fusion, and pain in the ligaments and tendons.Ankylosing spondylitis can also be diagnosed by X-rays of the back and pelvis or by physical examination. The pain related to the condition mostly worsens in the morning or after sitting for a prolonged period. The first line of treatment for AS is nonsteroidal anti-inflammatory drugs (NSAIDs). Some of these medications are sold over the counter; others require prescription. Some of the mentionable NSAIDs are Celecoxib, Diclofenac, and Meloxicam, among others.



Market Drivers

The ankylosing spondylitis treatment market is growing at a significant rate due to the increasing prevalence of ankylosing spondylitis and rising awareness about diagnostics and treatments for the disease. In addition, government initiatives and improving healthcare infrastructure are driving the market for ankylosing spondylitis treatment. Moreover, factors such as the high cost of treatment and lack of skilled surgeons and physiotherapists restrain the market from growing.